Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access for Nonconforming Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma
jRCT2053200162Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
Open-label, single-arm trial of lisocabtagene maraleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Bristol Myers Squibb. Primary endpoint: Safety. Started Dec 2021; status: recruiting.
02
Drugs
lisocabtagene maraleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2053200162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053200162.